Lumiracoxib

Lumiracoxib

Clinical data
Pregnancy category	AU: C
Routes of administration	Oral
ATC code	M01AH06 (WHO)
Legal status
Legal status	POM Red Stripe (Brazil) Withdrawn (Australia, New Zealand, Canada, UK, Germany, Austria, Belgium, Cyprus)
Pharmacokinetic data
Bioavailability	74% (oral)
Protein binding	>98%
Metabolism	Hepatic oxidation and hydroxylation (CYP2C9)
Elimination half-life	4 hours
Excretion	Renal and fecal
Identifiers
IUPAC name {2-[(2-chloro-6-fluorophenyl)amino]-5-methylphenyl} acetic acid
PubChem CID	151166
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}
Chemical and physical data
Formula	C15H13ClFNO2
Molar mass	293.72 g/mol

WikiDoc Resources for Lumiracoxib
Articles
Most recent articles on Lumiracoxib Most cited articles on Lumiracoxib Review articles on Lumiracoxib Articles on Lumiracoxib in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Lumiracoxib Images of Lumiracoxib Photos of Lumiracoxib Podcasts & MP3s on Lumiracoxib Videos on Lumiracoxib
Evidence Based Medicine
Cochrane Collaboration on Lumiracoxib Bandolier on Lumiracoxib TRIP on Lumiracoxib
Clinical Trials
Ongoing Trials on Lumiracoxib at Clinical Trials.gov Trial results on Lumiracoxib Clinical Trials on Lumiracoxib at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Lumiracoxib NICE Guidance on Lumiracoxib NHS PRODIGY Guidance FDA on Lumiracoxib CDC on Lumiracoxib
Books
Books on Lumiracoxib
News
Lumiracoxib in the news Be alerted to news on Lumiracoxib News trends on Lumiracoxib
Commentary
Blogs on Lumiracoxib
Definitions
Definitions of Lumiracoxib
Patient Resources / Community
Patient resources on Lumiracoxib Discussion groups on Lumiracoxib Patient Handouts on Lumiracoxib Directions to Hospitals Treating Lumiracoxib Risk calculators and risk factors for Lumiracoxib
Healthcare Provider Resources
Symptoms of Lumiracoxib Causes & Risk Factors for Lumiracoxib Diagnostic studies for Lumiracoxib Treatment of Lumiracoxib
Continuing Medical Education (CME)
CME Programs on Lumiracoxib
International
Lumiracoxib en Espanol Lumiracoxib en Francais
Business
Lumiracoxib in the Marketplace Patents on Lumiracoxib
Experimental / Informatics
List of terms related to Lumiracoxib

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Lumiracoxib (rINN) is a COX-2 selective inhibitor non-steroidal anti-inflammatory drug, manufactured by Novartis and still sold in few countries, including Mexico, South Africa, and Brazil, under the trade name Prexige (sometimes misquoted as "Prestige" by the media). The TARGET study (Therapeutic Arthritis Research and Gastrointestinal Event Trial) was conducted with more than 18,000 patients to test its gastrointestinal and cardiovascular safety against Naproxen and Ibuprofen and also study its efficacy against these two NSAIDs.

In November 2006, Prexige received marketing approval for all European Union countries through a common procedure called MRP. As of 2007, the Food and Drug Administration (FDA) has not yet granted approval for its sale in the United States.

Lumiracoxib has a different structure from the standard COX-2 inhibitors (e.g. celecoxib). It more closely resembles the structure of diclofenac (one chlorine substituted by fluorine, the phenylacetic acid has another methyl group in meta position), making it a member of the arylalkanoic acid family of NSAIDs. It binds to a different site on the COX-2 receptor than the standard COX-2 inhibitors. It displays extremely high COX-2 selectivity.

The FDA rejected Prexige as a trade name for lumiracoxib in 2003. The FDA Division of Medication Errors and Technical Support (DMETS) subsequently recommended against the alternative name Prexede. The planned trade name for lumiracoxib in the US has not been disclosed to the public.

On September 27, 2007, the US Food and Drug Administration issued a not approvable letter for lumiracoxib, requiring additional safety data.

Withdrawal from market

On August 11, 2007, Australia's Therapeutic Goods Administration (TGA, the Australian equivalent of the FDA) cancelled the registration of lumiracoxib in Australia due to concerns that it may cause liver failure.

According to the TGA's Principal Medical Adviser, Dr Rohan Hammett, as of 10 August 2007 the TGA had received 8 reports of serious adverse liver reactions to the drug, including two deaths and two liver transplants.

"The TGA and its expert advisory committee, the Adverse Drug Reactions Advisory Committee (ADRAC), have urgently investigated these reports. ADRAC has today recommended the cancellation of the registration of Lumiracoxib due to the severity of the reported side effects associated with this drug," Dr Hammett said.

"The TGA has taken this advice to cancel the registration of Lumiracoxib in order to prevent further cases of severe liver damage.

"It seems that the longer people are on the medicine, the greater the chance of liver injury. The TGA is, therefore, advising people to stop taking the Lumiracoxib immediately and to discuss alternative treatments with their doctor," Dr Hammett said.

New Zealand has followed suit with Australia in recalling Prexige.

On October 3, 2007, Health Canada requested sales of Prexige to stop. Novartis has agreed to the request and has taken steps to do so.On December 13, 2007, the European Medicines Agency recommended the withdrawal for Prexige from all EU markets.